Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Aerie Pharma (AERI): Few Hurdles Ahead Of Rhopressa Launch - Canaccord
-
Aerie Pharma (AERI): Path Cleared For Rhopressa Launch - Canaccord
-
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
-
Canaccord Genuity Reiterates Buy Rating and $56 PT on Aerie Pharma (AERI); 'No Surprise for ROCKET-4, Focus Remains MERCURY-2'
-
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
-
Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
-
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
-
UPDATE: Canaccord Genuity Upgrades Aerie Pharma (AERI) to Buy
-
Pre-Open Stock Movers 06/19 (AMCN) (AERI) (CAG) Higher; (SARA) (HWAY) (TKMR) Lower (more...)
-
Canaccord Genuity Downgrades Aerie Pharma (AERI) to Hold
-
Notable Analyst Rating Changes 07/03: (CREE) (ATHL) (TS) Upgraded; (RMD) (RGDO) ((NFX) Downgraded
-
Pre-Open Stock Movers 7/3: (DRL) (PETM) (APP) Higher; (RGDO) (NQ) (RGSE) Lower (more...)
-
Canaccord Genuity Starts Aerie Pharma (AERI) at Buy
-
Canaccord Genuity Starts Aerie Pharma (AERI) at Buy
-
Aerie Pharmaceuticals (AERI) IPO Opens Modestly Higher
-
aerie pharmaceuticals (AERI) Sees IPO Price of $12 - $14/Share
-
aerie pharmaceuticals (AERI) Files $57.5M IPO

